drugset
drugset / Trial / NCT05793684

AD816 Crossover Study

NCT05793684 ↗

Phase 2 Completed 25 enrolled Apnimed
RandomizedCrossoverDouble-blindTreatment

Summary

The VicTor Study is a randomized, double blind, placebo-controlled, 3-period, multiple-dose crossover study in participants with OSA.

Timeline

Start
2023-04-28
Primary completion
2023-11-09
Completion
2023-11-09

Outcome

Met primary endpoint

paper Vilo-trazo reduced AHI4 (mean difference (95% CI): 10.5 (6.6, 13.6) events/hour, p<0.001) PMID 40360261 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject AD816 Unknown — —
Subject Viloxazine Small molecule 500 mg —

Indications

obstructive sleep apnea syndrome